Latest Breaking News On - None of the janssen pharmaceutical companies - Page 3 : comparemela.com

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomRegion flamandeTamara werner kiechleAl awawdehJanssen cilag gmbCompanies of johnsonJanssen pharmaceutical companies of johnsonJanssen research developmentNone of the janssen pharmaceutical companiesAmerican college of cardiologyJanssen pharmaceutical companiesEuropean medicines agencyWorld health organization groupExchange commissionEuropean society of cardiology respiratoryMarketing authorisation application

New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Haemolytic Disease of the Foetus and Newborn (HDFN)

New Phase 2 Data Demonstrate Potential Benefit of Nipocalimab for Pregnant Individuals at High Risk of Early-Onset Severe Haemolytic Disease of the Foetus and Newborn (HDFN)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesOhio state universityMemorial hermann hospitalRegion flamandeKennethj moise jrKenneth moiseKatie abouzahrMoise kj jrHematology am soc hematol educ programFetal medicine foundation world congressEuropean unionNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonDrug administrationDepartment of women healthExchange commission

Janssen Announces Erdafitinib Improved Overall Survival

Confirmatory data from Cohort 1 of the Phase 3 THOR study showed greater than four-month improvement in median overall survival in patients treated with.

France generalRegion flamandeUnited statesMilenkovic petronicSipetic grujicics urothelialJanssen cilag gmYohann loriotKiran patelInstitut gustave roussyJanssen pharmaceuticaClinical developmentCompanies of johnsonAstex therapeuticsDrug administrationJanssen pharmaceutical companiesJanssen research development in phase

CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) Reduces

At 16 months median follow-up, cilta-cel significantly improved progression-free survival compared to two standard of care treatment regimens1 .

United statesRegion flamandeCiltacabtagene autoleucelEdmond chanAmerican society of clinical oncology annual meetingEuropean medicines agencyAmerican cancer societyCongress abstractJanssen biotech incJanssen research developmentJanssen pharmaceutical companiesAmerican society of clinical oncologyEuropean hematology associationEuropean commission grants conditional approvalLegend biotech united states incNone of the janssen pharmaceutical companies

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing.

Noord hollandUnited statesRachel kobosSatu glaweChristie corbettEastern cooperative oncology groupExchange commissionNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonEuropean medicines agencyJanssen pharmaceutical companiesEuropean commissionAmerican cancer societyAmerican society of clinical oncologyNational comprehensive cancer networkJanssen research development